Laurus Synthesishttp://www.laurussynthesis.com has inked a deal to collaborate with Epygenix Therapeutics for the development and manufacture of their lead candidate EPX-100. Laurus Synthesis will provide chemistry development services and manufacturing in support of an upcoming clinical trial for EPX-100 in adolescents suffering from Dravet syndrome. Like most genetic forms of epilepsy, Dravet syndrome represents an orphan indication with an unmet medical need. “Epygenix is proud to be su...